Market Cap 69.42M
Revenue (ttm) 0.00
Net Income (ttm) -80.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 168,960
Avg Vol 776,834
Day's Range N/A - N/A
Shares Out 31.56M
Stochastic %K 36%
Beta 1.75
Analysts Strong Sell
Price Target $11.17

Company Profile

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 207 8979
Website: acrivon.com
Address:
480 Arsenal Way, Suite 100, Watertown, United States
2outted
2outted Dec. 5 at 5:23 PM
$ACRV added more today
0 · Reply
Doudiane
Doudiane Dec. 4 at 5:39 PM
$ACRV the day this one hits 11$, you are all invited to Paris
0 · Reply
Hereinbama35
Hereinbama35 Dec. 4 at 5:38 PM
$ACRV Nothing like a slow, steady climb.
0 · Reply
Dani_G_German
Dani_G_German Dec. 4 at 5:37 PM
0 · Reply
2outted
2outted Dec. 4 at 4:18 PM
$ACRV I see this stock over $4$ soon, results soon
1 · Reply
Jstidd
Jstidd Dec. 4 at 4:01 PM
$ACRV a little pre-annoucement pop here? 🤞🏼
0 · Reply
Doudiane
Doudiane Dec. 4 at 10:05 AM
$ACRV they will announce the results when? They said H2 2025… we are 12/04… hopefully soon
1 · Reply
Doudiane
Doudiane Dec. 3 at 9:50 AM
$ACRV gonna explose soon i feel
1 · Reply
Jstidd
Jstidd Dec. 1 at 4:44 PM
$ACRV moving on up. this thing is a sleeping giant
0 · Reply
sssssssssssssAhmed
sssssssssssssAhmed Nov. 28 at 10:21 AM
$ACRV https://www.quiverquant.com/news/New%2BAnalyst%2BForecast%3A%2B%24ACRV%2BGiven%2B%2419.0%2BPrice%2BTarget?utm_source=chatgpt.com
0 · Reply
Latest News on ACRV
What To Buy After You Sell The Russell 2000

Apr 3, 2024, 3:07 AM EDT - 1 year ago

What To Buy After You Sell The Russell 2000

AVUV IJR IWM IWN MLYS NXT SKWD


Acrivon: Precision-Testing Your Trial Patients Before Enrolment

Mar 26, 2023, 9:53 AM EDT - 2 years ago

Acrivon: Precision-Testing Your Trial Patients Before Enrolment


Acrivon Therapeutics sets IPO price range

Nov 3, 2022, 7:52 AM EDT - 3 years ago

Acrivon Therapeutics sets IPO price range


Acrivon Therapeutics Begins U.S. IPO Rollout

Oct 19, 2022, 11:50 AM EDT - 3 years ago

Acrivon Therapeutics Begins U.S. IPO Rollout


2outted
2outted Dec. 5 at 5:23 PM
$ACRV added more today
0 · Reply
Doudiane
Doudiane Dec. 4 at 5:39 PM
$ACRV the day this one hits 11$, you are all invited to Paris
0 · Reply
Hereinbama35
Hereinbama35 Dec. 4 at 5:38 PM
$ACRV Nothing like a slow, steady climb.
0 · Reply
Dani_G_German
Dani_G_German Dec. 4 at 5:37 PM
0 · Reply
2outted
2outted Dec. 4 at 4:18 PM
$ACRV I see this stock over $4$ soon, results soon
1 · Reply
Jstidd
Jstidd Dec. 4 at 4:01 PM
$ACRV a little pre-annoucement pop here? 🤞🏼
0 · Reply
Doudiane
Doudiane Dec. 4 at 10:05 AM
$ACRV they will announce the results when? They said H2 2025… we are 12/04… hopefully soon
1 · Reply
Doudiane
Doudiane Dec. 3 at 9:50 AM
$ACRV gonna explose soon i feel
1 · Reply
Jstidd
Jstidd Dec. 1 at 4:44 PM
$ACRV moving on up. this thing is a sleeping giant
0 · Reply
sssssssssssssAhmed
sssssssssssssAhmed Nov. 28 at 10:21 AM
$ACRV https://www.quiverquant.com/news/New%2BAnalyst%2BForecast%3A%2B%24ACRV%2BGiven%2B%2419.0%2BPrice%2BTarget?utm_source=chatgpt.com
0 · Reply
aletz
aletz Nov. 27 at 6:57 PM
$ACRV https://www.biostockinfo.com/biotech-catalyst-ai-scanner-december-wk1/ ACRV having a great run, can it continue?
0 · Reply
Jstidd
Jstidd Nov. 25 at 2:15 PM
$ACRV PT of $19 💪
0 · Reply
Trinity031983
Trinity031983 Nov. 25 at 1:20 PM
$ACRV https://tipranks.onelink.me/WJho/hqupx22i
0 · Reply
JarvisFlow
JarvisFlow Nov. 25 at 11:46 AM
HC Wainwright & Co. updates rating for Acrivon Therapeutics ( $ACRV ) to Buy, target set at 19.
0 · Reply
Manonfire8
Manonfire8 Nov. 24 at 6:33 PM
$HOWL this has bottomed out and is the same reversion play as many other big runners this year $VTYX $GALT $ACRV $OCGN all went sub 1 dollar before the market recognized their true value. Similar structures, all with amazing data and platforms/drugs; the market will pour into this value play as well. I suggest loading up here!
0 · Reply
WhaleSharksHF
WhaleSharksHF Nov. 24 at 3:20 AM
$DFSC $ACRV $OPEN $OSRH $UFG $DFSC 🚀 Defense rocket on deck ready to melt your face. Join discord for degen nightwatch link in bio • $3.10 | $4.4M mcap | 1.3M float • Borrow cost 183% APR → shorts getting cooked • Q3 rev +330% → $1.4M, gross margin +879% • $48M Thales C4ISR deal + massive backlog • Ayrton Capital just loaded heavy bags • Multiple funds building new positions ARWEN production + intl orders incoming Comps KTOS MOBX CTM CYCU all ripped Target still $12+ Low float + real revenue = violent move coming Long & strong $DFSC 🔥
0 · Reply
JL_TradeZ
JL_TradeZ Nov. 23 at 9:21 PM
Main Watchlist 24/11 $OSRH has the strongest catalyst on the list with the Vaximm term sheet showing $20M upfront and up to $815M in milestones. Volume was huge and the float is small, so it has a real chance to continue as long as it holds above 0.62. $ACRV is still one of the cleanest daily charts. Earnings beat, strong cash, tiny float, and institutions loading. It’s sitting right under the 2.40–2.50 breakout zone and looks ready for continuation if 2.25–2.30 holds $UFG held 1 all week and the chart is tightening. Float is only 5M, revenue growth has been strong, and the company keeps dropping legit expansion updates. If volume hits Monday, it has clean room back toward 1.10–1.15. $PLUG held up well despite dilution and downgrades. Buyers defended 1.90 all week and it closed near 2. If it gets over 2.05–2.10, it has room for a squeeze into the mid 2s $OPEN still has attention after the warrant dividend and DE Shaw’s 6.4% stake. Volume stayed strong Friday and it bounced well
0 · Reply
JL_TradeZ
JL_TradeZ Nov. 22 at 10:30 PM
$ACRV has been one of the steadier biotech names lately. The balance sheet is clean with strong cash, almost no debt, and it’s trading at about half of its tangible book value. Institutions still own more than half the float and we saw a new 13G hit, plus multiple Form 4s last week that were only tax-related, not open-market selling. They also beat EPS estimates and continue to push progress on ACR-368 and ACR-2316, which are the main drivers behind the long-term story. For a small-cap biotech, the fundamentals are way better than most The chart has been trending up for months and held the higher low structure all week. It’s been curling back up and now sits under the 2.40-2.50 breakout that’s been blocking it. Volume stayed steady and every dip got bought, so the momentum is still there For Monday, I’m watching 2.25-2.30 to hold as support off open. If it holds, it has a clean shot to break over 2.40-2.50 and push toward 2.55-2.70. If the market isn’t dead, this has room for another leg
1 · Reply
2outted
2outted Nov. 21 at 10:52 PM
$ACRV Ken Griffin 13g
0 · Reply
JL_TradeZ
JL_TradeZ Nov. 21 at 10:49 PM
$ACRV https://www.benzinga.com/node/49018460
0 · Reply
JL_TradeZ
JL_TradeZ Nov. 21 at 10:46 PM
$ACRV 13G came in after hours. Just means a fund grabbed a stake, which is usually a good sign that someone with size is interested. Not insider selling or anything negative. Chart still holding fine and watching that 2.36 break to see if it wakes up
0 · Reply
bowlerhatsftw
bowlerhatsftw Nov. 21 at 3:45 AM
$ACRV ACRV
1 · Reply